drugset / Trial / NCT00236977

Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia

NCT00236977

Phase 3 Completed 182 enrolled American Regent, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the safety and efficacy of two forms of iron therapy for the treatment of anemia in non-dialysis dependent, chronic renal failure in patients receiving or not receiving erythropoietin.

Timeline

Start
2003-08
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ferrous Sulfate Diagnostic / imaging agent 325 mg Oral
Subject Iron sucrose Unknown 200 mg Intravenous
Subject Iron sucrose Unknown 500 mg Intravenous

Indications